Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter ...